Skip to main content
. 2009 Aug 4;100(11):2226–2233. doi: 10.1111/j.1349-7006.2009.01306.x

Figure 5.

Figure 5

 Kallistatin gene and the combinational therapies inhibit tumor angiogenesis. Representative tumor sections prepared from mice two weeks after treatment with pcDNA3.1 (control) (A), Kalli‐pcDNA3.1 (B), meloxicam (C), or Kalli‐pcDNA3.1 + meloxicam (D). Tumor microvessels in sections were fluorescently stained with anti‐CD31 Ab and counted in blindly chosen random fields to record microvessel density (E). †Significant difference in microvessel density from control. ‡Highly significant difference in microvessel density from control. Five tumors accessed per group. (F) Homogenates of tumors from mice treated with pcDNA3.1 (lane 1), Kalli‐pcDNA3.1 (lane 2), meloxicam (lane 3), or meloxicam + Kalli‐pcDNA3.1 (lane 4) were subjected to Western blot analysis with Abs against vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and β‐actin.